Prediction of activity for nonnucleoside inhibitors with HIV-1 reverse transcriptase based on Monte Carlo simulations

Journal of Medicinal Chemistry

Volumn 45, Issue 14, 2002, Pages 2970-2987

  Rizzo, Robert C ^a   Udier Blagović, Marina ^a   Wang, De Ping ^a   Watkins, Edward K ^a   Kroeger Smith, Marilyn B ^a   Smith Jr , Richard H ^a   Tirado Rives, Julian ^a   Jorgensen, William L ^a  

^a YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; BENZODIAZEPIN 2 ONE DERIVATIVE; BENZONITRILE; CARBOXANILIDE DERIVATIVE; EFAVIRENZ; EMIVIRINE; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; NEVIRAPINE; NEVIRAPINE DERIVATIVE; QUINOXALINE DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TALVIRALINE; THIAZOLE DERIVATIVE; TROVIRDINE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; COMPUTER SIMULATION; DRUG BINDING SITE; DRUG STRUCTURE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MONTE CARLO METHOD; NONHUMAN; VIRUS INFECTION;

ANILIDES; COMPUTER SIMULATION; HIV-1 REVERSE TRANSCRIPTASE; HYDROGEN BONDING; MODELS, MOLECULAR; MONTE CARLO METHOD; NEVIRAPINE; OXAZINES; PROTEIN BINDING; QUINOXALINES; REGRESSION ANALYSIS; REVERSE TRANSCRIPTASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; URACIL;

EID: 0037019283     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm010580q     Document Type: Article

References (63)

1. Molecular targets for aids therapy
2. The retroviral enzymes
3. Locations of anti-aids drug binding sites and resistance mutations in the 3-dimensional structure of HIV-1 reverse transcriptase: Implications for mechanisms of drug inhibition and resistance
4. HIV resistance to reverse transcriptase inhibitors
5. Molecular modeling studies of Hiv-1 reverse-transcriptase nonnucleoside inhibitors - Total-energy of complexation as a predictor of drug placement and activity
6. The role of nonnucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection
7. Synergistic inhibition of HIV-1 reverse transcriptase DNA polymerase activity and virus replication in vitro by combinations of carboxanilide nonnucleoside compounds
8. Prediction of binding affinities for tibo inhibitors of HIV-1 reverse transcriptase using monte carlo simulations in a linear response method
9. Monte Carlo calculations on HIV-1 reverse transcriptase complexed with the nonnucleoside inhibitor 8-Cl TIBO: Contribution of the L100I and Y181C variants to protein stability and biological activity
10. Estimation of binding affinities for hept and nevirapine analogues with HIV-1 reverse transcriptase via Monte Carlo simulations
11. Validation of a model for the complex of HIV-1 reverse transcriptase with sustiva through computation of resistance profiles
12. Antiviral drug design: Computational analyses of the effects of the L100I Mutation for HIV-RT on the binding of NNRTIs
13. New developments in anti-HIV chemotherapy
14. Novel compounds in preclinical/early clinical development for the treatment of HIV infections
15. Free energy changes in solution
16. Computational approaches to molecular recognition
17. Free energy calculations: Applications to chemical and biochemical phenomena
18. Free energy calculations: A breakthrough for modeling organic chemistry in solution
19. A new method for predicting binding affinity in computer-aided drug design
20. An extended linear response method for determining free energies of hydration
21. Free energies of solvation in chloroform and water from a linear response approach
22. Estimation of binding free energies for HIV proteinase inhibitors by molecular dynamics simulations
23. Binding free energy calculations for P450cam-substrate complexes
24. Cyclic HIV-1 protease inhibitors derived from mannitol: Synthesis, inhibitory potencies, and computational predictions of binding affinities
25. Ligand binding affinity prediction by linear interaction energy methods
26. What determines the van der Waals coefficient beta in the LIE (Linear Interaction Energy) method to estimate binding free energies using molecular dynamics simulations?
27. Binding affinities for sulfonamide inhibitors with human thrombin using Monte Carlo simulations with a linear response method
28. Estimation of the binding affinities of FKBP12 inhibitors using a linear response method
29. Prediction of properties from simulations: Free energies of solvation in hexadecane, octanol and water
30. Estimation of binding affinities for selective thrombin inhibitors via Monte Carlo simulations
31. Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent nonnucleoside inhibitors
32. Crystal structures of HIV-1 reverse transcriptase in complex with carboxanilide derivatives
33. High-resolution structures of HIV-1 RT from four RT-inhibitor complexes
34. Structures of Tyr188Leu mutant and wild-type HIV-1 reverse transcriptase complexed with the nonnucleoside inhibitor HBY 097: Inhibitor flexibility is a useful design feature for reducing drug resistance
35. Phenylethylthiazolylthiourea (PETT) non-nucleoside inhibitors of HIV-1 and HIV-2 reverse transcriptases. Structural and biochemical analyses
36. Structure of HIV-1 RT/Tibo R-86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors
37. Comparison of simple potential functions for simulating liquid water
38. Development and testing of the opls all-atom force field on conformational energetics and properties of organic liquids
39. i) and concentration of inhibitor which causes 50 per cent inhibition (150) of an enzymatic reaction
40. What can we learn from molecular recognition in protein-ligand complexes for the design of new drugs?
41. Structure-based design, synthesis, and biological evaluation of conformationally restricted novel 2-alkylthio-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4- (3H)-ones as nonnucleoside inhibitors of HIV-1 reverse transcriptase
42. 5-Alkyl-2-(alkylthio)-6-(2,6-dihalophenylmethyl)-3,4-dihydropyrimidin-4(3H) -ones: Novel potent and selective dihydro-alkoxybenzyl-oxopyrimidine derivatives
43. Synthesis and antiviral activity of deoxy analogues of 1[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) as potent and selective anti-HIV-1 agents
44. Synthesis and antiviral activity of 6-benzyl analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) as potent and selective anti-HIV-1 agents
45. A new class of HIV-1-specific 6-substituted acyclouricine derivatives: Synthesis and anti-HIV-1 activity of 5-substituted or 6-substituted analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT)
46. Structure-activity-relationships of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine analogues: Effect of substitutions at the C-6 phenyl ring and at the C-5 position on anti-HIV-1 activity
47. Identification of novel thiocarboxanilide derivatives that suppress a variety of drug-resistant mutant human immunodeficiency virus type 1 strains at a potency similar to that for wild-type virus
48. Activity of various thiocarboxanilide derivatives against wild-type and several mutant human immunodeficiency virus type 1 strains
49. Novel nonnucleoside inhibitors of HIV-1 reverse-transcriptase. 1. Tricyclic pyridobenzodiazepinones and dipyridodiazepinones
50. 2-Amino-6-arylsulfonylbenzonitriles as nonnucleoside reverse transcriptase inhibitors of HIV-1
51. Synthesis and evaluation of analogues of Efavirenz (Sustiva) as HIV-1 reverse transcriptase inhibitors
52. Synthesis and evaluation of benzoxazinones as HIV-1 reverse transcriptase inhibitors. Analogues of Efaviren(SUSTIVA)
53. Preclinical evaluation of HBY 097, a new nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 replication
54. Phenehylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relationship studies of PETT analogues
55. Phenethylthiazolylthiourea (PETT) compounds as a new class of HIV-1 reverse transcriptase inhibitors. 2. Synthesis and further structure-activity relationship studies of PETT analogues
56. Synthesis and anti-Hiv-1 activity of 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-Jk][1,4]benzodiazepin-2(1h)-one (Tibo) derivatives
57. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: Implications for drug resistance